EBRI research New angles on Alzheimer’s immunotherapy

Data: 2015-12-18

La versione in italiano sarà presto disponibile. Di seguito la versione in inglese.

During the Society for Neuroscience (SfN) meeting held in Chicago on 17-21 October 2015, EBRI researcher Giovanni Meli reported new updates on his research performed in collaboration with Antonino Cattaneo.

Giovanni Meli’s contribution at SfN has been highlighted by Alzforum, the most prominent scientific forum on Alzheimer’s disease:

http://www.alzforum.org/news/conference-coverage/preclinical-research-offers-new-angles-immunotherapy

Meli and colleagues from the laboratory of Antonino Cattaneo at EBRI have demonstrated for the first time that it is possible to selectively target, inside the cell, certain oligomeric Aβ conformers, but not the Aβ precursor protein (APP) or the monomeric Aβ. See also the paper published in Nature Communications:

http://www.nature.com/ncomms/2014/140527/ncomms4867/full/ncomms4867.html

New research studies will focus on how intrabodies can prevent cellular damage by oligomeric forms of Aβ inside cells, performing innovative preclinical studies that offer promising perspectives for immunotherapy in Alzheimer’s disease, as reported in the Alzforum review.